Patents by Inventor Nathan C. Ihle

Nathan C. Ihle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
    Patent number: 7176310
    Abstract: This invention is directed to compound of the following formula (I): wherein R1, R2, R3 and R4 are as described herein. These compounds and pharmaceutical compositions containing the compounds are useful in treating inflammatory disorders in mammals.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: February 13, 2007
    Assignee: UCB SA
    Inventors: Theodore A. Baughman, Jim P. Boyce, Ihab S. Darwish, J. Jeffry Howbert, Nathan C. Ihle, Randy W. Jackson, Scott C. Jeffrey, Dean Maeda, Kraig M. Yager
  • Integrin receptor antagonists
    Patent number: 5952306
    Abstract: Fibrinogen receptor antagonists having the formula ##STR1## for example ##STR2## which are useful for inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.
    Type: Grant
    Filed: January 14, 1997
    Date of Patent: September 14, 1999
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Mark E. Duggan, James J. Perkins, Cecilia A. Hunt, Amy E. Krause, John H. Hutchinson, Benny C. Askew, Karen M. Brashear, Nathan C. Ihle
  • Guainidino, formamidino, amino and related compounds for inhibiting osteoclast-mediated bone resorption
    Patent number: 5929120
    Abstract: Compounds of the following general structureX--Y--Z-Aryl-A--B, ##STR1## which inhibit osteoclast mediated bone resorption.
    Type: Grant
    Filed: January 30, 1998
    Date of Patent: July 27, 1999
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Mark E. Duggan, William F. Hoffman, Nathan C. Ihle
  • Integrin antagonists
    Patent number: 5919792
    Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: July 6, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, George D. Hartman, William F. Hoffman, Nathan C. Ihle
  • Fibrinogen receptor antagonists
    Patent number: 5854245
    Abstract: Fibrinogen receptor antagonists having the structureX--Y--Z--A--Band pharmaceutically acceptable salts, wherein X is a 5, 6 or 7 membered aromatic or nonaromatic ring, and Y is a 5 or 6 membered aromatic ring, e.g.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: December 29, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, George D. Hartman, Steven D. Young, Nathan C. Ihle
  • Fibrinogen receptor antagonists
    Patent number: 5852045
    Abstract: Fibrinogen receptor antagonists having the structure, for example, of ##STR1## for example ##STR2##
    Type: Grant
    Filed: October 15, 1996
    Date of Patent: December 22, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Ben C. Askew, George D. Hartman, Mark E. Duggan, Steven D. Young, John H. Hutchinson, John S. Wai, Melissa S. Egbertson, Laura M. Vassallo, Laura A. Libby, Amy E. Krause, Wasyl Halczenko, Nathan C. Ihle
  • Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption
    Patent number: 5741796
    Abstract: Compounds of the following general structure X-Y-Z-Aryl-A-B, for example, ##STR1## which inhibit osteoclast mediated bone resorption. Specifically, the compounds are useful for treating mammals suffering from a bone condition caused or mediated by increased bone resorption, who are in need of such therapy. The compounds may be administered in oral dosage forms such as tablets, capsules, e.g. sustained release capsules, powders, granules, and suspensions.
    Type: Grant
    Filed: September 26, 1996
    Date of Patent: April 21, 1998
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Mark E. Duggan, William F. Hoffman, Nathan C. Ihle
  • Method for incorporating radioactive phosphoric acid solutions in concrete
    Patent number: 4442028
    Abstract: A method for incorporating radioactive phosphoric acid solutions in concrete is described wherein the phosphoric acid is reacted with Ca(OH).sub.2 to form a precipitate of hydroxyapatite and the hydroxyapatite is mixed with portland cement to form concrete.
    Type: Grant
    Filed: July 8, 1982
    Date of Patent: April 10, 1984
    Assignee: The United States of America as represented by the United States Department of Energy
    Inventors: Gary A. Wolf, Jeffrey W. Smith, Nathan C. Ihle